Antiproliferative and antimetastatic characterization of an exo-heterocyclic androstane derivative against human breast cancer cell lines by Kulmány, Ágnes Erika et al.
Biomedicine & Pharmacotherapy 140 (2021) 111728
Available online 19 May 2021
0753-3322/© 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Original article 
Antiproliferative and antimetastatic characterization of an exo-heterocyclic 
androstane derivative against human breast cancer cell lines 
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Single-cell drug effect 
Breast cancer 
A B S T R A C T   
Cancer in general, and specifically gynaecological neoplasms, represents a major public health issue worldwide. 
Based on the effect of sex hormones on breast tumorigenesis and prognosis, as well as on the development of 
breast cancer metastases, modification of the steroid skeleton is a hotspot of research for novel anticancer agents. 
Numerous recent studies support that minor modifications of the androstane skeleton yield potent anti-
proliferative and antimetastatic drug candidates. The aim of the present study was to assess the antitumor and 
antimetastatic properties, as well as the mechanism of action of a D-ring-modified exo-heterocyclic androstadiene 
derivative named 17APAD. The test compound was found to be highly selective towards human breast cancer- 
derived cell lines (MCF-7, T47D, MDA-MB-361, MDA-MB-231) compared to non-cancerous fibroblast cells (NIH/ 
3T3), and exerted superior effect compared to the clinically applied reference drug cisplatin. Changes in MCF-7- 
and MDA-MB-231 cell morphology and membrane integrity induced by the test substance were assessed by 
fluorescent double staining. Cell cycle disturbances were analyzed by flow cytometry, and concentration- 
dependent alterations were detected on breast cancer cell lines. Mitochondrial apoptosis induced by the test 
compound was demonstrated by JC-1 staining. Inhibitory effects on metastasis formation, including the inhi-
bition of migration, invasion and intravasation were investigated in 2D and 3D models. Significant anti- 
migratory and anti-invasive effects on MCF-7 and MDA-MB-231 cells were detected after 24 h exposure in 2D 
wound healing and Boyden-chamber assays. The anti-intravasative properties of 17APAD were evident after 4 h 
of incubation in a co-culture 3D circular chemorepellent-induced defects (CCID) assay, and the level of inhibition 
at concentrations ≥2 µM was comparable to that exerted by the focal adhesion kinase inhibitor defactinib. Single 
cell mass cytometry revealed that chemosensitive subpopulations of MDA-MB-231 cells engaged to apoptosis 
were less positive for EGFR, CD274, and CD326, while the percentage of cells positive for GLUT1, MCT4, Pan- 
Keratin, CD66(a,c,e), Galectin-3 and TMEM45A increased in response to 17APAD treatment. Finally, the novel 
androstane analogue 17APAD had an outstanding inhibitory effect on tumour growth in the 4T1 orthotopic 
murine breast cancer model in vivo after 2 weeks of intraperitoneal administration. These findings support that 
substitution of the androsta-5,16-diene framework with a N-containing heterocyclic moiety at C17 position 
yields a molecular entity rational to be considered for design and synthesis of novel, effective antitumor agents, 
and 17APAD is worth further investigation as a promising anticancer drug candidate.   
1. Introduction 
Cancer represents a significant public health burden and is the 
second leading cause of death worldwide. Based on the GLOBOCAN 
2018 survey of population-based cancer registries, malignancies are the 
main cause of death before age 70 in developed countries. Collecting 
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incidence and mortality data on 36 cancer types from 185 countries, this 
overview estimated 18.1 million new cancer cases and 9.6 million 
cancer-related deaths in 2018. Although trends and distributions greatly 
differ from region to region, a significant rise in both the incidence and 
mortality is expected over the next two decades. Among gynaecological 
malignancies, breast cancer is associated with the highest incidence and 
mortality. Among females, it is the most commonly diagnosed tumour 
type (11.6%, with 2.1 million new cases) and the leading cause of cancer 
death (6.6%, with ~627,000 deaths) worldwide [1–4]. 
Several risk factors responsible for the development of breast cancer 
have been identified, including genetic predisposition (e.g. mutations of 
BRCA1 and BRCA2 genes), aging, higher overall estrogen exposure 
(nulliparity, late age at first childbirth, long-term hormone therapy), 
high breast density, a history of atypical hyperplasia, and lifestyle effects 
(Western-style diet, obesity, alcohol consumption) [5,6]. Hereditary 
(mutation of BRCA2 and androgen receptor genes), hormonal (e.g. 
hyperprolactinaemia, long-term treatment with anti-androgens and es-
trogens) or environmental (external radiation) risk factors and aging can 
lead to breast cancer in men as well, but its incidence is less than 1% of 
all cancers in men and less than 1% of all breast cancers [7,8]. 
Population-based breast cancer screening services are of crucial 
importance for early diagnosis, which is key to improve the chance for 
successful therapy [9,10]. However, while early-stage breast cancer is 
often curable, breast tumours detected in an advanced stage still have 
generally poor prognosis, thus novel treatment options are eagerly 
awaited. 
Due to the well-known effects of estrogens and androgens on cell 
proliferation and growth of hormone-dependent tumour tissues, one of 
the prominent areas of pharmacological research focuses on chemical 
modifications of the steroid skeleton to develop potent antitumor com-
pounds. Structures of nuclear steroid receptors and their agonist and 
antagonist ligands are highly conserved, so minor modifications of the 
endogenous ligands at the appropriate positions, such as in the A- or D- 
ring, can yield compounds with completely novel biological activities 
[11,12]. Several recent studies have reported on modified androstane 
derivatives that exert potent enzyme-inhibitory, antiproliferative or 
antimetastatic activities in breast cancer cell lines [13]. Enzymes that 
modulate steroid biosynthesis and metabolism (e.g. aromatase, 
17β-hydroxysteroid dehydrogenase, etc.) play a crucial role in main-
taining physiological hormone levels. Thus, the inhibition of these 
enzyme proteins significantly reduces the level of endogenous estrogens 
and androgens, which is essential in the therapy of hormone-sensitive 
tumours. Aromatase is one of the most important enzymes involved in 
steroid hormone biosynthesis, mediating the conversion of androgens 
into estrogens (e.g. the biosynthesis of estrone from androstenedione or 
estradiol from testosterone). Therefore, aromatase inhibitors of steroidal 
(formestane and exemestane) or non-steroidal types are an integral part 
of the available treatment strategies for estrogen-dependent breast 
cancer, as well as of the research for novel drug candidates (Fig. 1). One 
of these research areas focuses on the functionalization of androstene-
dione at various positions [14]. As a part of these efforts, Bansal et al. 
have reported on novel 16-imidazolyl substituted steroidal compounds, 
of which two, 16β-(imidazol-1-yl)-4-androstene-3,17-dione and 
16β-(imidazol-1-yl)-androsta-1,4-diene-3,17-dione were demonstrated 
to exert a potent aromatase inhibitory activity with IC50 values of 0.18 
µM and 0.168 µM, respectively [15] (Fig. 1). Another important enzyme 
of steroid biosynthesis is 17β-hydroxysteroid dehydrogenase (17β-HSD), 
whose subtypes catalyze numerous steroidogenic reactions and inacti-
vation of steroid hormones. Types 1 and 7 of 17β-HSD convert estrone 
into estradiol, thus the inhibition of these enzyme subtypes can hinder 
the proliferation of estrogen-dependent tumour tissues. Bellavance et al. 
and Wang et al. have reported on 17β-substituted 4-methyl-4-aza-5R--
androstane derivatives, namely INH1 and INH7, which remarkably 
decrease the reduction of estrone into estradiol via the inhibition of 
17β-HSD1 and/or 17β-HSD7 with IC50 values ranging from 189 nM to 
451 nM. In addition, both INH1 and INH7 were demonstrated to sup-
press cell proliferation in MCF-7 and T47D breast cancer cells lines. 
Their antiproliferative activity is mediated by cell cycle arrest in the 
G0/G1 phase via the inhibition of cyclin D1 and the activation of p21 
proteins, as well as by modulating the levels of anti-apoptotic and 
Fig. 1. Some representatives of anticancer agents derived from natural steroids and the chemical structure of 17APAD.  
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pro-apoptotic proteins (Bcl-2, Bik), manifesting as a measurable 
shrinkage of malignant masses in an MCF-7 xenograft tumour model 
[16,17]. 
Similarly, A- or D-ring modified androstane analogues were also 
reported to exert pronounced antiproliferative activity in different 
cancer cell lines, especially against breast cancer cells. Scherbakov et al. 
synthesized numerous pyrimidine- and dihydrotriazine-derivatives of 
steroids in the androstane and estrane series, and the most promising 
compounds were demonstrated to have a growth inhibitory potential 
(IC50 values ranging from 7.4 to 21.6 µM) on MCF-7 and MDA-MB-231 
cell lines. Additionally, the lead molecule bearing a dihydrotriazine 
moiety at the C16 position was shown to be selective towards MCF-7 
breast cancer cells, with 50% inhibition of the activity of the estrogen 
receptor α without exerting any estrogen agonist activities [18]. Ajdu-
kovic and co-workers described the antiproliferative and proapoptotic 
properties of some novel A-ring-modified 17α-picolyl and 17(E)-picoli-
nylidene androstane derivatives, demonstrated in 6 different human 
malignant cell lines (MCF-7, MDA-MB-231, PC-3, HeLa, A549, HT-29), 
showing preferable selectivity towards the MCF-7 and PC-3 cells [19]. 
As the majority of cancer-related deaths are caused by metastases, 
modern drug research is partly directed towards the development of 
antimetastatic compounds. Wang et al. reported on E-salignone amide 
derivatives synthesized from epiandrosterone and androsterone, exert-
ing favourable antimigratory effects and inhibiting the EGF-induced 
invasion of MDA-MB-231 cells [20]. 
In a previous study, we characterized a novel group of 17-(4′-formyl) 
pyrazolylandrosta-5,16-dienes – structurally related to dehydroepian-
drosterone – that exerted promising antiproliferative activity on 
adherent breast cancer cell lines, and had a potent inhibitory effect on 
C17,20-lyase, a rat testicular enzyme [21] (Fig. 1). The aims of the present 
study were to explore tumour selectivity, mechanism of action and 
antimetastatic properties of a potential drug candidate of this series 
(17APAD). 
2. Materials and methods 
2.1. Chemicals and cell cultures 
3β-Hydroxy-17-[1′-(4"-cyanophenyl)-4′-hydroxymethyl-1′H-pyr-
azol-3′-yl]androsta-5,16-diene (17APAD; Fig. 1) was synthesized as re-
ported previously [21]. MCF-7, MDA-MB-231 and NIH/3T3 cell lines 
were purchased from ECACC (European Collection of Cell Cultures, 
Salisbury, UK), and the 4T1 cell line was acquired from ATCC (American 
Tissue Culture Collection, Manassas, Virginia, USA). A telomerase 
immortalized human lymphatic endothelial cell line (T1S1/iLEC) was 
established and characterized by the Medical University of Vienna 
(Vienna, Austria). MCF-7, MDA-MB-231 and NIH/3T3 cells were 
maintained in Eagle’s Minimum Essential Medium (EMEM) supple-
mented with 10% fetal bovine serum (FBS), 1% non-essential amino acid 
solution and 1% penicillin, streptomycin and amphotericine B mixture 
at 37 ◦C, in humidified atmosphere containing 5% carbon dioxide (CO2). 
iLECs, owning to their special requirements, were grown in EGM-2 MV 
medium (EGM-2 MV BulletKit, Lonza), under the same conditions. The 
4T1 mouse breast cancer cells were cultured in RPMI medium com-
plemented with 10% FBS, 1% non-essential amino acid mixture and 1% 
antibiotic solution, and were kept in a CO2 incubator at 37 ◦C. Passage 
numbers of all cells used in the experiments were less than 25. All media, 
supplements, chemicals and kits used for the experiments and cell 
culturing, were obtained from Sigma-Aldrich Ltd. (Budapest, Hungary) 
unless otherwise specified. 
2.2. Antiproliferative (MTT) and tumour selectivity assays 
Promising antiproliferative properties of 17APAD on four adherent 
breast cancer cell lines with different receptor expression profiles have 
been published earlier [21]. For a more detailed exploration of these 
experimental data, the standard antiproliferative assay was repeated on 
non-cancerous fibroblast cells (NIH/3T3) under the same conditions 
[22]. NIH/3T3 cells were seeded onto 96-well plates in a density of 5000 
cells/well, and were treated with increasing concentrations of the drug 
candidate (0.1–30 µM). After 72 h of incubation, 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide solution (MTT, 5 mg/mL in 
phosphate buffer) was added. After 4 h of exposure, the supernatants 
were gently removed and the precipitated blue formazan crystals were 
dissolved in 100 µL dimethyl sulfoxide (DMSO). Absorbance values were 
recorded by a microplate reader (Stat Fax 2100, Awareness Technolo-
gies, Westport, CT, USA) at 545 nm, and data of normalized six-point 
dose-response curves were fitted by the GraphPad Prism 5.0 software 
(GraphPad Software, San Diego, CA, USA). Untreated cells were used as 
a control, and a stock solution of 17APAD was prepared with DMSO. The 
maximum concentration of DMSO (0.3%) exerted no substantial effect 
on the proliferation of the cells we utilized. 
2.3. Hoechst 33258–propidium iodide fluorescent double staining 
To characterize the changes in cell morphology and cell membrane 
integrity after treatment with 17APAD, fluorescent double staining was 
carried out. MCF-7 cells were seeded onto 96-well plates in a density of 
5000 cells/well, were incubated overnight in a CO2 thermostat, and then 
were treated with different concentrations of 17APAD for 24 h. Next, the 
cells were stained by lipophilic Hoechst 33258 (5 μg/mL, HO) and hy-
drophilic propidium iodide (3 μg/mL, PI) for 1 h under the same cir-
cumstances described for cell culturing above. After refreshing the 
medium on the samples, at least 10 images/condition were taken by a 
Nikon Eclipse TS100 fluorescence microscope (Nikon Instruments 
Europe, Amstelveen, The Netherlands) equipped with appropriate op-
tical blocks for Hoechst 33258 (excitation: 360/40 nm bandpass filter, 
emission: 460/50 nm bandpass filter and 400 nm dichromatic mirror) 
and propidium iodide (excitation: 500/20 nm bandpass filter, emission: 
520 nm longpass filter and 515 nm dichromatic mirror), and the images 
were analyzed by the QCapture Pro software (QImaging, Surrey, British 
Columbia, Canada). Nuclei were counted (300–900 cells/image, 
depending on the applied concentration of 17APAD), and the ratios of 
different cell populations were expressed. 
2.4. Apoptosis assay 
To further characterize the proapoptotic property of 17APAD, 
Annexin V-Alexa 488– propidium iodide (PI) combined fluorescent 
staining was performed with flow cytometry detection as described 
previously [23]. MCF-7 and MDA-MB-231 cells were grown on 24-well 
cell culture plates (80,000 cells/well) and were treated with increasing 
concentrations (1, 2, 4 and 8 µM) of 17APAD. After 24 h of incubation, 
the cells were washed with phosphate buffered saline (PBS), harvested 
by trypsin and pooled with collected supernatants. After centrifugation 
(1400 rpm for 5 min at room temperature), the cells were resuspended 
in Annexin V binding buffer (ABB; 0.01 M HEPES, 0.14 M NaCl and 
2.5 mM CaCl2, pH = 7.4) and were stained with Annexin V-Alexa 488 
(LifeTechnologies, Waltham, MA, USA) for 15 min in dark, at room 
temperature. PI (10 µg/mL) in ABB was added directly before acquisi-
tion to dilute (5x) Annexin V-Alexa 488. For each sample 10,000 events 
were recorded by a FACSCalibur cytofluorimeter (BD Biosciences, San 
Jose, CA, USA), and the data were analyzed by the CellQuest™ software 
(Becton Dickinson, New Jersey, USA). 
2.5. Cell cycle analysis 
In order to gain a more detailed insight into the effects of 17APAD on 
cell cycle in the tested breast cancer cell lines, cell cycle analysis was 
accomplished as described previously [24]. Briefly, estrogen and pro-
gesterone receptor positive MCF-7 and triple negative MDA-MB-231 cell 
lines were seeded onto 24-well plates (80,000 cells/well). The samples 
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were treated with increasing concentrations of 17APAD for 48 h or 72 h, 
washed with PBS and collected after trypsinization. Cells were pooled 
with the collected supernatants and PBS from washing, and were 
centrifuged at 1400 rpm for 5 min at room temperature. Pellets were 
resuspended and stained by our DNA staining solution (10 µg/mL PI, 
0.1% Triton-X, 10 µg/mL RNase A, and 0.1% sodium citrate dissolved in 
PBS) for 30 min in dark, at room temperature. Detection of DNA content 
from at least 20,000 cells/sample were carried out by a FACSCalibur 
flow cytometer, and the obtained data were analyzed by the Kaluza 
Analysis Software (Beckman Coulter, Brea, California, USA). Untreated 
cells were considered as control. Hypodiploid subG1 phases were 
regarded as evidence of a late apoptotic event. 
2.6. Mitochondrial membrane potential assay (JC-1 staining) 
To elucidate the mechanism of action of 17APAD, the origin of 
induced apoptosis was examined by the JC-1 assay as described previ-
ously [25]. JC-1 is a voltage-sensitive dye which can accumulate and 
aggregate in mitochondria, and emits red light when the mitochondrial 
membrane potential is physiological. In contrast, when the mitochon-
drial membrane potential is disrupted, the accumulation of JC-1 is 
reduced, leading to a shift from red to green fluorescence. MCF-7 and 
MDA-MB-231 human breast cancer cells and 4T1 mouse mammary 
tumour cells were maintained and harvested under standard conditions 
described above, and the cell suspension was seeded onto 24-well plates 
in the density of 105 cells/well. After the administration of 17APAD and 
incubation for 12 h, the cells were washed with PBS, trypsinized and 
collected, pooled with the corresponding supernatant and centrifuged at 
2000 rpm for 5 min. Next, pellets were re-suspended in JC-1 (Chemo-
dex, St. Gallen, Switzerland) solution containing 5 μg/mL dye, and were 
incubated for 15 min at 37 ◦C. Finally, the red and green fluorescence 
signals of cells were detected on FL2 (585/42 nm) – FL1 (530/30 nm) 
channels by the FACSCalibur flow cytometer. In each analysis, 10,000 
events were recorded and data analysis was carried out by the Cell-
QuestTM software (Becton Dickinson, New Jersey, USA). 
2.7. Wound-healing assay 
The MCF-7 cell suspension was prepared in EMEM medium supple-
mented with 2% FBS, 1% non-essential amino acid solution and 1% 
penicillin, streptomycin and amphotericine B mixture, and it was 
implanted into special silicone inserts (Ibidi GmbH, Gräfelfing, Ger-
many) placed on 12-well plates, in a density of 20,000 cells/well. After 
an overnight incubation, the inserts were gently removed, the cells were 
wash with PBS, and were treated with low concentrations of 17APAD. 
The size of cell-free areas were determined by the ImageJ software 
(National Institutes of Health, Bethesda, Maryland, USA), based on im-
ages taken at 0, 24 and 48 h post-treatment. 
2.8. Boyden-chamber assay 
Special Boyden-chambers were applied to identify treatment effects 
on cancer cells’ invasion capacity. These inserts contain two medium- 
filled compartments separated by a PET membrane with a pore size of 
8 µm and a thin layer of matrigel basement matrix as an in vitro model of 
the extracellular environment. Suspension of highly invasive MDA-MB- 
231 cells, prepared in serum-free EMEM medium supplemented with 
sub-antiproliferative concentrations of 17APAD, were nested into the 
upper chamber, onto prehydrated membrane, while the EMEM medium 
supplemented with 10% FBS was used as chemoattractant in the lower 
chamber. After 24 h of incubation, the supernatants and non-invading 
cells were removed cautiously with a cotton swab, and the membranes 
were washed with PBS twice. Samples were fixed in ice cold 96% 
ethanol, and were stained by 1% crystal violet dye for 30 min in dark, at 
room temperature. Images (at least 3 per insert) were taken by a Nikon 
Eclipse TS100 microscope, and invading cells were counted and 
compared to untreated control samples. 
2.9. Circular chemorepellent-induced defects assay (CCID) 
As a 3D model of intravasation, a circular chemorepellent-induced 
defects assay was performed in co-culture to assess the inhibitory ac-
tivity of 17APAD on metastasis formation. Tumour spheroids were 
prepared from MCF-7 cells, and iLEC human lymphendotelial cells were 
grown to almost 100% confluency on 24-well plates under cell culturing 
conditions. Cancer cells were harvested by trypsin and resuspended in 
EMEM medium supplemented with methylcellulose solution (in a final 
concentration of 0.3%), and were seeded onto U-bottom 96-well plates 
in a density of 3000 cells/well. The plates were centrifuged (1500 rpm, 
15 min, room temperature) and the samples were grown for approxi-
mately 3 days to form spheroids. Upon starting the analysis, the iLEC 
monolayer was stained by CellTracker Green dye (ThermoFisher Sci-
entific, Waltham, Massachusetts, USA) for 1 h at 37 ◦C. Next, the fluo-
rescent labelled endothelial barrier was washed by PBS and 
preincubated with 17APAD for 20 min. Spheroids with appropriate size 
and shape were selected, washed and preincubated with 17APAD for 
20 min as well. After pretreatment, tumour spheroids were placed on the 
lymphendotelial cell monolayer and were incubated with 17APAD for 
4 h in CO2 atmosphere at 37 ◦C. Spheroids and iLEC monolayer treated 
with complete medium supplemented with 0.1% DMSO were used as 
controls. To assess lymphendothelial defects resembling intravasation, 
images of at least 12 spheroids per condition from three biologically 
independent samples were taken by a fluorescent Axiovert microscope 
(Zeiss GmbH, Jena, Germany). CCID areas and the size of spheroids were 
evaluated by the Zen Little 2012 software (Zeiss GmbH, Jena, Germany). 
2.10. Single cell mass cytometry 
Single cell mass cytometry was carried out as described previously 
[24]. Briefly, MDA-MB-231 cells were plated (4 × 105 cells/well in 
6-well plates) in 3 mL EMEM medium containing 8 µM 17APAD, and 
were incubated for 72 h. Control samples were left untreated. Three 
separate experiments were performed at three different time points. 
After treatment for antibody staining, three technical replicate wells 
were pooled. The cells were washed with PBS and were liberated by 
Accutase (Corning Life Sciences, Ny, USA), centrifuged (5 min, 350g), 
re-suspended in PBS and counted using a Bürker chamber and trypan 
blue viability dye (Sigma-Aldrich) before being processed for mass 
cytometry staining. Viability of the cells was determined by cisplatin 
staining (5 µM 195Pt, Fluidigm, CA, USA) for 3 min on ice in 300 µL 
PBS. Samples were diluted with 1500 µL Maxpar Cell Staining Buffer 
(MCSB, Fluidigm) and were centrifuged at 350g for 5 min. Non-specific 
binding of the antibodies was avoided by incubating the cells with 
TruStain FcX (Biolegend, CA, USA), 2.5 µL in 50 µL MCSB (PBS con-
taining blocking proteins) for 10 min. Cells were centrifuged (350g, 
5 min) and suspended in 50 µL MCSB, and the resultant antibody mix 
(Table 1) was added to 50 µL of fresh master pool of antibodies. The 
following antibodies were conjugated with metal tags in-house: 
anti-CA9, anti-GLUT1, anti-MCT4 and anti-TMEM45A, using a Maxpar 
Table 1 
Antibodies used for mass cytometry.  
Catalogue number Supplier Target Metal tag 
3170009B Fluidigm EGFR 170Er 
3156026B Fluidigm CD274 (PD-L1) 156Gd 
3141006B Fluidigm CD326 (EpCam) 141Pr 
MAB1418 R&D Systems GLUT1 154Sm 
sc-376140 Santa Cruz Biotech. MCT4 171Yb 
3162027A Fluidigm Pan-Keratin 162Dy 
3149018B Fluidigm CD66-a,c,e 149Sm 
3153026B Fluidigm Galectin-3 (Gal-3) 153Eu 
orb357227 Biorbyt TMEM45A 169TM  
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metal labelling kit and strictly following to the instructions of the 
manufacturer (Fluidigm). All the antibodies were titrated prior to the 
experiment in order to determine their optimal level of dilution. 
After incubating the samples for 60 min at 4 ◦C, the antibodies were 
washed by 2 mL MCSB and centrifuged at 300g for 5 min, twice. The 
pellet was suspended in the residual volume. The cells were fixed in 
1.6% formaldehyde (freshly diluted from 16% Pierce formaldehyde with 
PBS, Thermo Fisher Scientific) and incubated at room temperature for 
10 min. Next, the cells were centrifuged at 800g for 5 min. Cell-ID DNA 
intercalator (191Ir/193Ir, Fluidigm) was added in 1:1000 dilution in 
Maxpar Fix and Perm buffer (Fluidigm) and the sample was incubated 
overnight at 4 ◦C. The sample was centrifuged at 800g for 5 min, then it 
was washed with 2 mL MCSB and centrifuged again at 800g for 5 min. 
The cells were suspended in 1 mL PBS (for WB injector) and were 
counted in a Bürker chamber after centrifugation. For the acquisition, 
the concentration of cells was set to 0.3 × 106/mL in a cell acquisition 
solution (CAS, Fluidigm) containing 10% EQ Calibration Beads (Fluid-
igm). The cells were filtered through a 30 µm gravity filter (Celltrics, 
Sysmex Partec, Japan) and were acquired freshly. Mass cytometry data 
were analyzed by the Cytobank software (Beckman Coulter). Cell debris 
and aggregates were excluded, and singlets were determined by manual 
gating using the 191Ir and 193Ir DNA intercalators. Next, untreated single 
cells and cells with hampered viability (195Pt+) were manually gated 
positive for the investigated markers. The t-SNE (t-distributed stochastic 
neighbour embedding) analysis (iterations = 1000, perplexity = 30, 
theta = 0.5), was carried out on 1.5 × 104 events of untreated singlets 
versus treated single cells with drug-sensitivity (195Pt+). The before-after 
plots based on pooled data of three biological replicates demonstrate the 
percentage of cells positive for a given marker in untreated control 
samples compared to the percentage of MDA-MB-231 cells sensitive to 
8 µM 17APAD. 
2.11. In vivo mouse breast cancer model 
To examine the antineoplastic properties of 17APAD in vivo, an 
orthotopic mouse breast cancer model was used according to the 
methodology utilized in a previous study [26]. The experiments were 
executed in accordance with the EU rules (2010/63/EU) on animal 
experimentation and ethics. The experimental protocol was approved by 
the responsible governmental agency (National Food Chain Safety Of-
fice) in concordance with the ethical clearance No. XXIX./128/2013. 
Two groups (test vs. control, 7 animals per group) of BALB/c mice 
(weighing 18–26 g) were housed in a sterile, IVC cage system protected 
by a Hepa filter, at ambient temperature of 25 ◦C. On day 1 of the 
experiment, 120,000 4T1 breast carcinoma cells, maintained, harvested 
and re-suspended in FCS-free RPMI medium, were injected into the 
orthotopic mammary pad of each animal. On day 12, the animals were 
randomized into test vs. control groups. The mean tumour size was 
approximately equal in each group (mean values between 22 and 
25 mm3). The test group was treated with 25 mg/kg 17APAD dissolved 
in a mixture of DMSO/Solutol HS 15/saline (1:3:10) once daily, intra-
peritoneally, five times a week for 2 weeks. The control group was 
treated with the vehicle mixture. Tumour size and body mass were 
measured daily (d2 x D x 0.5, where d and D are minor and major 
tumour diameters, respectively). After the treatment period, the animals 
were sacrificed, primary tumour tissues were removed and their weights 
were measured. 
2.12. Statistical analysis 
The GraphPad Prism version 5.01 software was used for statistical 
analysis. Statistical significance was estimated by one-way analysis of 
variance (ANOVA) followed by the Dunnett post-test. All presented re-
sults are means ± SEM of at least three replicates. *, ** and *** indicate 
P < 0.05, P < 0.01 and P < 0.001 compared to control, respectively. 
3. Results 
3.1. 17APAD selectively inhibited cell proliferation of breast cancer cell 
lines 
Remarkable growth inhibitory effect of our test compound 17APAD 
on human breast cancer cell lines was demonstrated previously, indi-
cating that 17APAD is more potent than the clinically applied control 
cisplatin [21]. Tumour selectivity (TS) investigated in our study is 
expressed as the ratio of the IC50 values for 17APAD and cisplatin control 
(CIS) on breast cancer and non-cancerous fibroblast cells (Table 2). TS 
indices for 17APAD and cisplatin were ≤0.473 and ≥1.387, respec-
tively, indicating a higher tumour selectivity of 17APAD in human 
breast cancer cell lines compared to cisplatin. 
3.2. 17APAD induced programmed cell death via the activation of 
mitochondrial pathway of apoptosis in breast cancer cells 
Changes in cell morphology and cell membrane integrity of breast 
cancer cell were visualized by fluorescent nuclei staining using Hoechst 
33258 and propidium iodide dyes after 24 h exposure to 2 or 4 μM 
17APAD. Fluorescence microscopy analysis revealed early apoptotic 
cells with bright blue fluorescence owing to the penetration of Hoechst 
33258 dye, while secondary necrotic nuclei eradiated red fluorescence 
owing to the penetration of propidium iodide. Significant increments 
were observed in the number of MCF-7 cells showing early signs of 
apoptosis or the natural outcome of the complete apoptotic program 
(Fig. 2). 
While the microscopic detection of fluorescent staining has limita-
tions regarding cell number count and the separation of early vs. late 
apoptotic and necrotic cells, flow cytometry allows of detecting a higher 
number of events and a more precise distinction of different cell pop-
ulations. In both types of human breast cancer cells (MCF-7 and MDA- 
MB-231), 17APAD induced a concentration-dependent activation of 
phosphatidylserine exposure, which can be regarded as an indicator of 
late apoptotic cells (late apoptosis: AnnV+/PI+) without the presence of 
a massive necrotic cell population (necrosis: AnnV-/PI+) (Fig. 3). 
To elucidate the possible mitochondrial origin of apoptosis, a JC-1 
assay was performed. Green fluorescence of the monomer form of JC- 
1 in cells with depolarized mitochondrial membrane were recorded by 
a flow cytometer, and its quantitative analysis showed significant, 
concentration-dependent increments in the proportion of cells with 
damaged mitochondrial function in all cell lines 12 h post-treatment 
with 17APAD (Fig. 4). 
3.3. 17APAD induced cell-cycle arrest 
Cell cycle disturbances induced by 17APAD were assessed by cell 
cycle analysis. A concentration-dependent rise of hypodiploid subG1 cell 
populations, regarded as a marker of induced apoptosis, were observed 
in both cell lines (MCF-7, MDA-MB-231) (Fig. 5). Compared to untreated 
control, >12-fold and >8-fold changes were detected in the MCF-7 and 
MDA-MB-231 cell lines, respectively. Moreover, in the MCF-7 cell line, 
considerable elevations in the proportion of G2/M phases at the expense 
Table 2 
Calculated IC50 values and tumour selectivity (TS) indices for 17APAD and 
cisplatin (CIS), assessed on human breast cancer cell lines and a non-cancerous 
fibroblast cell line (NIH/3T3).  
Cell line IC50 (μM) TS17APAD IC50 CIS (μM) TSCIS 
MCF-7 1.40* 0.368 5.78# 2.143 
T47D 1.20* 0.316 9.78# 3.626 
MDA-MB-361 1.60* 0.473 3.74# 1.387 
MDA-MB-231 1.80* 0.421 19.13# 7.093 
NIH/3T3 3.75 – 2.70 – 
Note: * and # indicate literature data [21,27]. 
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of the G1 phase were detected after 48 h of treatment (results of analysis 
72 h post-treatment are presented in Supplementary Material). Under 
the same conditions, the highly invasive, triple negative breast cancer 
cell line MDA-MB-231 showed signs of G2/M cell cycle arrest and a 
modest reduction of the proportion of cells in the G1 phase 48 h after 
17APAD treatment. These changes were even more pronounced 72 h 
post-treatment (Fig. 6). 
3.4. 17APAD reduced migration, invasiveness and intravasation of breast 
cancer cells 
To determine the anti-migratory effect of 17APAD, changes in the 
size of cell-free areas were measured at 0, 24 h and 48 h post-treatment 
using samples with reduced serum-containing medium. A reduction of 
cell-free gaps, produced by special silicon inserts, was demonstrated by 
image analysis of wound closure. A significant decrease in wound 
healing was detected at 24 h and 48 h post-treatment even when sub- 
antiproliferative concentrations of 17APAD (i.e. <10% of the anti-
proliferative threshold value in the 72 h MTT assay) were applied, 
indicating a remarkable inhibition of tumour cell migration in cell lines 
treated with our test compound (Fig. 7). 
Besides cell migration, cellular invasion and infiltration of the sur-
rounding tissues are crucial to the development of tumour metastases. 
Therefore, we supplemented our wound healing assay of cellular 
migration with a special Boyden chamber assay as the extracellular 
environment of primary tumours, to study cellular invasion. For this 
purpose, because of non-invasive characteristic of MCF-7 cells, the 
highly invasive MDA-MB-231 breast cancer cell line was selected. In this 
experimental system, a noticeable decline of the invasive potential of 
MDA-MB-231 cells was observed as soon as 24 h post-treatment upon 
applying sub-antiproliferative concentrations (0.1 μM and 0.3 μM) of 
17APAD (Fig. 8). 
Available 2D assay data indicate a promising antimetastatic property 
of 17APAD, thus a co-culture circular chemorepellent-induced defects 
Fig. 2. 17APAD induced the accumulation of 
apoptotic and secondary necrotic cell pop-
ulations. Intact (A), early apoptotic (B), late 
apoptotic (C) and necrotic (D) MCF-7 nuclei 
stained by Hoechst 33258 (blue fluorescence, 
left panels) and propidium iodide (red fluores-
cence, right panels) after 24 h of treatment with 
2 µM 17APAD were analyzed by fluorescent 
microscopy at 400× magnification. The per-
centages of intact, apoptotic and necrotic cell 
populations were calculated (E). Data represent 
mean ± SEM. *, ** and *** indicate significant 
differences between 17APAD-treated and un-
treated control samples at P < 0.05, P < 0.01 
and P < 0.001, respectively (For interpretation 
of the references to colour in this figure legend, 
the reader is referred to the web version of this 
article).   
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assay was carried out to demonstrate antimetastatic activity in a 3D 
model of intravasation. After 4 h of treatment with 17APAD at a con-
centration of ≥2 µM, a remarkable and concentration-dependent 
decrease in the size of cell-free areas were observed on the confluent 
lymphendothelial cell monolayer underneath the tumour spheroids 
(Fig. 9). At a concentration of 4 µM, 17APAD reduced the areas of cell- 
free gaps by approximately 25%, which is comparable to the inhibitory 
effect of defactinib, a potent focal adhesion kinase (FAK) inhibitor agent 
currently investigated in clinical trials, and used as a positive control in 
our experiments. 
3.5. 17APAD induced changes in the expression level of 9 specific 
carcinoma markers in triple-negative breast cancer cells 
In order to characterize the chemosensitive subpopulations of MDA- 
MB-231 cells, nine carcinoma markers were investigated at single cell 
resolution following treatment with 8 µM 17APAD. The 
multidimensional analysis, the visualization of t-distributed stochastic 
neighbour embedding (viSNE), revealed the clonal heterogeneity of 
single-cell effects induced by 17APAD on the MDA-MB-231 cell line. The 
area of viSNE plots unequivocally discriminated between untreated 
control and 17APAD-sensitive cells. The colour changes of single cells 
detected upon treatment are proportional to the expression level of the 
specific carcinoma markers defining various subpopulations of MDA- 
MB-231 cells (Fig. 10A). After 72 h of incubation the percentage of 
cells positive for EGFR, CD274 (PD-L1), and CD326 (EpCAM) showed a 
gradual decrease within the drug-sensitive population, as determined by 
manual gating. On the contrary, the cells engaged to apoptosis showed 
an increased expression of GLUT1, MCT4, Pan-Keratin, CD66 (a,c,e), 
Galectin-3 and TMEM45A (Fig. 10B). 
Fig. 3. 17APAD exerted a proapoptotic effect both in MCF-7 and MDA-MB-231 cells. Representative dot-plot figures and percentages of viable (AnnV-/PI-), early 
apoptotic (AnnV+/PI-), late apoptotic (AnnV+/PI/), and necrotic (AnnV-/PI+) populations of MCF-7 (A–B) and MDA-MB-231 (C–D) cells. Cells were treated with 
17APAD for 24 h or were left untreated for control. A concentration-dependent increase in the rate of late apoptotic and necrotic fractions were observed in both cell 
lines, while the ratio of early apoptotic cells was elevated in the MDA-MB-231 and was reduced in the MCF-7 cell line. Data are presented as mean ± SEM. *, ** and 
*** indicate P < 0.05, P < 0.01 and P < 0.001, respectively, compared to control. 
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Fig. 4. 17APAD induced a loss of mitochondrial membrane integrity in breast cancer cell lines. Proportions of MCF-7 (B), MDA-MB-231 (D) and 4T1 (F) cells with 
depolarized mitochondrial membrane 12 h post-treatment and their representative dot-plot graphs showing treatment effects upon treatment with the highest 
concentration of 17APAD (A, C, E) are presented compared to untreated control. Values are mean ± SEM. * and *** indicate P < 0.05 and P < 0.001, respectively, 
compared to control. 
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3.6. Treatment of 17APAD highly reduced the tumour growth rate in 4T1 
mouse breast cancer model in vivo 
A 4T1 orthotopic mouse breast cancer model, accepted as an excel-
lent in vivo model of breast cancer development and metastasis [28,29] 
was used to test the antimetastatic properties of 17APAD. The test group 
of animals was administered 17APAD intraperitoneally, for 2 weeks at a 
dose of 25 mg/kg. As compared to the untreated control group, the 
mean tumour weight was significantly reduced in the treated group, 
from 971.8 mg to 504.1 mg. Besides, tumour growth curves indicate 
that the progression of tumour allografts significantly slowed down after 
the fourth day of the treatment compared to the controls (Fig. 11). 
Importantly, no serious or life-threatening side effects were observed in 
the experimental group. 
4. Discussion 
Molecules with a steroidal skeleton are ubiquitously distributed in 
nature, and include fungal sterols, phytosterols and steroid hormones in 
animals and humans. These natural products are responsible for a wide 
range of essential physiological functions, such as the maintenance of 
cellular structure and communication within the organism. Since the 
primary functions of sexual steroids are strongly associated with tissue 
development and proliferation, these mediators are also involved in the 
progression of several malignant disorders of such as breast, ovarian, 
prostate and colorectal cancers [30]. 
Several recent studies have demonstrated that modifying of the 
structure of endogenous human sexual steroids (estrogens and andro-
gens) at the appropriate positions, especially at the A- and/or D-rings 
(including the incorporation of new substituents like heterocyclic rings) 
may yield effective and potent semi-synthetic or synthetic derivatives 
with a wide spectrum of biological activities, while preserving the 
favourable pharmacological and pharmacokinetic properties of the ste-
roid frame (such as the rigid skeleton and lipophilicity) [13]. Some of 
these molecular products are already an integral part of oncotherapy 
(abiraterone) or are currently undergoing clinical trials (galeterone) 
based on experimental evidence supporting their promising in vivo ac-
tivities. Many steroid analogues applied as therapeutic agents share a 
common characteristic: they are generally substituted at the C17 posi-
tion with a proton donor or acceptor exo-heterocyclic ring that alters the 
molecule’s binding affinity to its receptors, leading to fundamentally 
altered biological properties compared to the parent compound 
[31–34]. 
Nuclear hormone receptors, such as estrogen or androgen receptors 
have highly conserved protein structures, characterized by a ligand- 
binding region consisting of 12 helices. The hydrogen bonds between 
the 3-keto group and the side chains at residues Q711 and R752, as well 
as between the 17β-OH group and the side chains at N705 and T877, or 
moieties mimicking these bonds play an essential role in the activation 
of the androgen receptor [35,36]. Upon designing effective, novel 
anticancer drug candidates with a sterane skeleton, all these structural 
requirements should be considered in order to avoid undesirable side 
effects of hormonal origin. Based on our previous research and literature 
data, D-ring substituted androstane analogues containing the heterocy-
clic ring pyrazole were designed and synthesized. Favourable anti-
proliferative properties of this molecular family have been reported on 
breast cancer cell lines, thus the most promising compound, 17APAD 
was selected for further investigation in the current study. Determining 
its mechanism of action would facilitate the design of potent anticancer 
and antimetastatic steroid analogues [21,27,37]. 
The IC50 values of our drug candidate 17APAD did not exceed 2 µM 
on breast cancer cell lines, while cisplatin, used as a positive control, 
showed the same level of inhibitory effect in the concentration range 
between 3.74 and 19.13 µM. Furthermore, the tumour selectivity index 
of 17APAD was found to range from 0.316 to 0.473, while the same 
index for cisplatin exceeded 1 (1.39–7.09), supporting a higher selec-
tivity of 17APAD in breast cancer cell lines. These findings are in 
agreement with literature data for other structurally related compounds, 
including abiraterone [21,38,39]. 
Regarding the mechanism of action of any promising antineoplastic 
compounds, destroying tumour cells by inducing programmed cell death 
is a crucial touchstone of effectiveness. The early steps of this process 
can be specified by morphological changes at the cell level, including 
chromatin condensation in early apoptotic cells and loss of membrane 
integrity in necrotic and secondary necrotic cells. To visualize these 
phenomena, Hoechst–propidium iodide fluorescent DNA staining was 
applied on MCF-7 cells after 24 h incubation with different concentra-
tions of 17APAD. Significant increases in the proportion of apoptotic and 
necrotic cell populations were observed in MCF-7 samples at concen-
trations ≥2 µM, indicating a potent proapoptotic characteristic of 
17APAD. Additionally, annexin V-Alexa488/propidium iodide fluores-
cent labelling was carried out using flow cytometry. A remarkable 
elevation of the proportion of late apoptotic cells, and a significant but 
less prominent increase in the proportion of necrotic cell populations 
were observed in both the MCF-7 and MDA-MB-231 human mammary 
carcinoma cell lines after 24 h incubation with the androstadiene 
analogue 17APAD. 
To further elaborate the mechanism of action of 17APAD, cell cycle 
analysis was carried out by flow cytometry on these two cell lines (MCF- 
7, MDA-MB-231). In case of the MCF-7 samples, a considerable elevation 
in the proportion of cells in the G2/M phase at the expense of the G1 
phase was revealed. The highly invasive, triple negative breast cancer 
cell line MDA-MB-231 seemed to be less sensitive, however, signs of the 
same cell cycle distributions were detected at 48 h after 17APAD 
Fig. 5. 17APAD (1, 2, 4 or 8 µM) induced significant and concentration-dependent elevations in the proportion of apoptotic sub-G1 cell populations in the MCF-7 (A) 
and MDA-MB-231 cell lines (B) 48 h post-treatment. Untreated cells were used as control. Data are presented as mean ± SEM. ** and *** indicate P < 0.01 and 
P < 0.001, respectively, compared to control. 
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Fig. 6. 17APAD induced cell cycle disturbances in MCF-7 (A, B) and MDA-MB-231 (C–F) cells, as detected 48 h (A–D) and 72 h (E, F) post-treatment. A considerable 
elevation in the ratio of cells in the G2/M phase and a reduction in the proportion of cells in G0/G1 phase were evident by cell cycle analysis. Data are presented as 
mean ± SEM. *, ** and *** indicate P < 0.05, P < 0.01 and P < 0.001, respectively, compared to control. 
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treatment, and these alterations became even more pronounced at 72 h 
post-treatment. This finding is in line with recent studies indicating that 
D-ring-modified androstane derivatives typically require 48 h of incu-
bation to induce cell cycle anomalies [27,37]. Furthermore, the pro-
portion of the hypodiploid subG1 fraction, regarded as the apoptotic 
population, increased in a concentration-dependent manner in both cell 
lines, supporting the proapoptotic property of 17APAD. 
In a previous study, Li et al. reported on the potent antiproliferative 
and apoptosis-inducing features of an agent showing a high degree of 
structural similarity to 17APAD (Fig. 1). This compound, 17β-(1-phenyl- 
4-((ethylamino)methyl)-3-pyrazolyl)androst-5,16-dienes-3β-ol], has 
been demonstrated to exert pronounced growth inhibitory activity in 
293 T (human kidney), A549 (lung carcinoma), HeLa (cervical epi-
theloid carcinoma) and MCF-7 (breast cancer) cell lines with IC50 values 
ranging from 0.53 to 7.39 µM. In addition, this androstane derivative 
was reported to induce nuclear condensation and appearance of 
apoptotic bodies in HeLa cells, visualized by Hoechst 33342 staining. 
Finally, it was reported to induce significant elevations of the apoptotic 
cell population using annexin V-FICT/PI staining and increase of the S 
phase proportion demonstrated by cell cycle analysis [40]. 
The morphological alterations specific to apoptosis are attributable 
to the cascades of biochemical interaction elicited by intrinsic or 
Fig. 7. 17APAD reduced/inhibited migration of breast cancer cells. Quantified rates of wound closure were significantly diminished in the presence of 17APAD. 
Graphs indicate the percentage of cell-free areas at 24 h (A) and 48 h (B) post-treatment in the MCF-7 cell line compared to control. Representative images of reduced 
wound healing at 0, 24 and 48 h post-treatment (C). Data are presented as mean ± SEM. ** and *** indicate P < 0.01 and P < 0.001, respectively, compared 
to control. 
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extrinsic initiation. Voltage-sensitive JC-1 staining indicated an 
impairment of mitochondrial membrane potential after 12 h of 17APAD 
treatment, corroborating that our test substance activates the intrinsic 
signal transduction mechanisms of apoptosis in human (MCF-7, MDA- 
MB-231) and murine (4T1) breast cancer cell lines. 
It is generally accepted that the majority of deaths from solid tumors 
are caused by metastases, thus, the identification of drug-modifiable 
targets involved in the development and growth of metastases, and 
research for novel drug candidates capable to interfere with metastasis 
formation are eagerly required to reduce cancer mortality [41]. The role 
of sexual steroidal hormones in the process of metastasis formation is 
incompletely understood and is currently investigated. Regarding the 
highly invasive, triple negative breast cancer cell lines (MDA-MB-231 
and MDA-MB-453), Giovannelli et al. have reported that androgens 
promote tumour invasiveness via the AR/Src/PI3-K complex, so pro-
gression may be reduced by antiandrogen administration [42–45]. The 
first steps of the metastatic cascade are migration and invasion of cancer 
cells through the basement membrane to reach the extracellular matrix 
and neighbouring tissues. In our study 17APAD significantly hindered 
the migration of MCF-7 cells after 24 h of exposure, and a remarkable, 
>20% difference in wound-closure rate of control and treated samples 
was detected at 48 h after adding 300 nM of 17APAD to the MCF-7 
samples in a wound healing assay. Regarding the MDA-MB-231 cell 
line, the number of invasive tumour cells greatly decreased after 24 h of 
treatment with sub-antiproliferative, nanomolar concentrations 
(100 nM and 300 nM) of 17APAD. 
However, cell motility alone is not sufficient for metastasis forma-
tion: migrating cells need to enter the circulatory system via lymphatic 
or blood vessels. Intravasation necessarily includes the interaction be-
tween cancer cells and the endothelial barrier, resulting in gap 
formation via different pathways [46]. As a 3D, co-culture model of the 
interactions between tumour cells and the endothelial monolayer, we 
implemented a circular chemorepellent-induced defects assay. The size 
of cell free-areas on the iLEC monolayer under MCF-7 tumour spheroids 
decreased by 30% after 4 h treatment with 17APAD at a concentration of 
8 µM. This level of inhibition was comparable to that induced by 
defactinib, a potent focal adhesion kinase inhibitor currently investi-
gated in clinical trials [47,48]. 
Targeting cell surface markers such as EGFR, CD274 or CD326, 
associated with the malignant characteristic and poor prognosis of solid 
tumours, is reported to enhance the chemosensitivity of tumour cells 
[49–51]. In agreement with these previous findings, 17APAD-sensitive 
subpopulations of MDA-MB-231 cells showed decreased expression of 
EGFR, CD274, and CD326 in our study. Besides, perturbation of the 
mitochondrial membrane potential induced by 17APAD, leading to 
oxidative stress in MDA-MB-231 cells was also shown. In line with the 
literature, we have found the metabolic reprogramming of cells may 
induce GLUT1 and MCT4 expression [52,53]. Increased expression of 
these regulators of breast cancer cell survival support glycolytic meta-
bolism and lactate secretion as compensatory mechanisms getting acti-
vated upon oxidative stress [54,55]. Increased GLUT1 expression has 
also been reported in association with increased chemosensitivity in 
triple negative breast cancer cell lines [56]. Increased expression of 
Pan-Keratins on cell surface detected in our study (the clone C11 anti-
body detects keratins: 4, 5, 6, 8, 10, 13 and 18) can also be regarded as 
markers for increased sensitivity to host defence mechanisms, as 
Pan-Keratins are receptors for clearance by phagocytic cells [57]. In 
contrast, the carcinoembryonic antigen-related cell adhesion molecules 
(CEACAM) recognized by the antibody used in our study (CD66a =
CEACAM1, CD66c = CEACAM6, CD66e = CEACAM5) are carcinoma 
Fig. 8. 17APAD reduced the invasiveness of triple-negative breast cancer cells (MDA-MD-231). The anti-invasive potential of the test substance is demonstrated by 
representative images (A), and it is expressed by the percentage of invading cells in the Boyden chamber containing different concentrations of 17APAD using EMEM 
medium supplemented with 10% FBS as chemoattractant for MDA-MB-231 cells (B). Data are presented as mean ± SEM. * and *** indicate P < 0.05 and P < 0.001, 
respectively, compared to untreated control samples. 
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Fig. 9. 17APAD hindered gap formation underneath breast cancer spheroids. The decrease in the size of cell-free areas was comparable to that induced by a potent 
focal adhesion kinase (FAK) inhibitor defactinib used as a positive control. Reduction of the size of cell-free areas induced by defactinib (A) and 17APAD (B) after 4 h 
treatment on MCF-7/iLEC model, and representative images of cancer spheroids (upper panel in phase contrast microscopy) and beneath cytotracker-stained 
endothelial monolayer (lower panel fluorescence microscopy of the same microscopical frame) are presented (C). Data represent mean ± SEM. *** indicates 
P < 0.001 compared to the untreated control. 
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Fig. 10. Representative multidimensional visualization of 9 carcinoma marker proteins in the MDA-MB-231 cell line treated with 8 µM 17APAD and evaluated at 
single cell resolution 72 h post-treatment (A). Within the chemosensitive cell population, 17APAD reduced the percentage of cells positive for EGFR, CD274 and 
CD326, and increased the percentage of cells positive for GLUT1, MCT4, Pan-Keratin, CD66(a,c,e), Galectin-3, TMEM-45A (B). *, ** and *** indicate P < 0.05, 
P < 0.01 and P < 0.001, respectively, compared to control. 
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markers used in routine diagnostics, and are involved in cancer pro-
gression, angiogenesis and the development of metastasis [58]. Inter-
estingly, the cells positive for CD66(a,c,e) overlapped with the 
population of cells positive for TMEM45A. The increase of both 
Galectin-3 and TMEM45A detected in a subpopulation of MDA-MB-231 
cells have previously been reported to be responsible for chemo-
resistance and cancer cell survival under hypoxic conditions [59,60]. 
Finally, to determine whether the favourable antitumor properties of 
the exo-heterocyclic androstadiene derivative 17APAD demonstrated in 
vitro are also evident in vivo, a BALB/c mice model of 4T1 breast cancer 
was used. This orthotopic animal model mimics stage IV, highly inva-
sive, triple-negative human breast cancer. After 2 weeks of intraperito-
neal administration of 17APAD tumour growth rate was substantially 
reduced, without any serious side effects detected. Upon dissection, the 
mean weight of primary tumours was found to be reduced by approxi-
mately 50% compared to vehicle-treated controls. 
In conclusion, our experimental data support the promising anti-
proliferative and antimetastatic effects of 3β-hydroxy-17-[1′-(4"-cyano-
phenyl)-4′-hydroxymethyl-1′H-pyrazol-3′-yl]androsta-5,16-diene 
(17APAD for short). Apoptosis-induction via activating the intrinsic 
pathway of programmed cell death accompanied by moderate tumour 
selectivity, as well as the potent anti-migratory, anti-invasive and anti- 
intravasative effects of the test substance have been identified as part 
of its mechanism of action. In light of these findings, 17APAD is worth 
further investigation as a potential drug candidate with antiproliferative 
and antimetastatic properties but besides in vivo testing on mice, further 
toxicological and pharmacokinetic characterization of this compound is 
necessary to provide a forecast of its potential biological, health and 
environmental impacts. Besides, our findings support that the substitu-
tion of the androsta-5,16-diene framework at C17 position with a N- 
containing heterocyclic moiety yields a molecular entity rational to be 
considered for design and synthesis of novel, effective antitumor agents. 
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Efficient access to novel androsteno-17-(1′ ,3′,4′)-oxadiazoles and 17β-(1′,3′,4′)- 
thiadiazoles via N-substituted hydrazone and N,N′-disubstituted hydrazine 
intermediates, and their pharmacological evaluation in vitro, Eur. J. Med. Chem. 
98 (2015) 13–29, https://doi.org/10.1016/j.ejmech.2015.05.010. 
[39] L.L. Romero-Hernández, P. Merino-Montiel, S. Meza-Reyes, J.L. Vega-Baez, 
Ó. López, J.M. Padrón, S. Montiel-Smith, Synthesis of unprecedented steroidal 
spiro heterocycles as potential antiproliferative drugs, Eur. J. Med. Chem. 143 
(2018) 21–32, https://doi.org/10.1016/j.ejmech.2017.10.063. 
[40] J. Li, H. Huo, R. Guo, B. Liu, L. Li, W. Dan, X. Xiao, J. Zhang, B. Shi, Facile and 
efficient access to Androsten-17-(1′,3′,4′)-pyrazoles and Androst-17β-(1′,3′,4′)- 
pyrazoles via Vilsmeier reagents, and their antiproliferative activity evaluation in 
vitro, Eur. J. Med. Chem. 130 (2017) 1–14, https://doi.org/10.1016/j. 
ejmech.2017.02.033. 
[41] H. Dillekås, M.S. Rogers, O. Straume, Are 90% of deaths from cancer caused by 
metastases? Cancer Med 8 (2019) 5574–5576, https://doi.org/10.1002/ 
cam4.2474. 
[42] J.N. Lichterman, R. Post, L. Menken, B. Saad, J. Delgado, L. Sall, M. Karr, 
Pi Kozlowski, K. Degenhardt, A novel role for 17-В estradiol and testosterone in 
osteosarcoma tumorigenesis and metastasis, JCO 35 (2017), e23012, https://doi. 
org/10.1200/JCO.2017.35.15_suppl.e23012. 
[43] C. Boni, M. Pagano, M. Panebianco, A. Bologna, N.M.A. Sierra, R. Gnoni, 
D. Formisano, G. Bisagni, Therapeutic activity of testosterone in metastatic breast 
cancer, Anticancer Res 34 (2014) 1287–1290. 
[44] A. Majumder, M. Singh, S.C. Tyagi, Post-menopausal breast cancer: from estrogen 
to androgen receptor, Oncotarget 8 (2017) 102739–102758, https://doi.org/ 
10.18632/oncotarget.22156. 
[45] P. Giovannelli, M. Di Donato, F. Auricchio, G. Castoria, A. Migliaccio, Androgens 
induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K 
complex assembly, Sci. Rep. 9 (2019) 4490, https://doi.org/10.1038/s41598-019- 
41016-4. 
[46] S.P.H. Chiang, R.M. Cabrera, J.E. Segall, Tumor cell intravasation, Am. J. Physiol. 
Cell Physiol. 311 (2016) C1–C14, https://doi.org/10.1152/ajpcell.00238.2015. 
[47] D.A. Fennell, P. Baas, P. Taylor, A.K. Nowak, D. Gilligan, T. Nakano, J.A. Pachter, 
D.T. Weaver, A. Scherpereel, N. Pavlakis, J.P. van Meerbeeck, S. Cedrés, L. Nolan, 
H. Kindler, J.G.J.V. Aerts, Maintenance defactinib versus placebo after first-line 
chemotherapy in patients with merlin-stratified pleural mesothelioma: 
COMMAND—a double-blind, randomized, phase II study, J. Clin. Oncol. 37 (2019) 
790–798, https://doi.org/10.1200/JCO.2018.79.0543. 
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